Loading clinical trials...
Loading clinical trials...
Phase II Study of Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
Conditions
Interventions
Osimertinib
Bevacizumab
Locations
1
China
The Second Afiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Start Date
October 1, 2017
Primary Completion Date
July 1, 2020
Completion Date
June 1, 2021
Last Updated
June 11, 2020
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Second Affiliated Hospital of Nanchang University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions